

• **Name:** Sung-Eun Lee

• **Affiliation/Current Position:** Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea/ Associate professor

• **Country:** Republic of Korea

• **Educational Background:**

March 1997 – February 2003 Bachelor's degree
The Hanyang Univ. of Korea, Seoul, Korea
March 2009 – February 2013 Ph.D. degree
The Catholic Univ. of Korea, Seoul, Korea

• **Professional Experiences:**

March 2003 – February 2004 Internship
The Hanyang Univ. of Korea, Seoul, Korea
March 2005 – February 2009 Residency,
Department of Internal Medicine,
The Catholic Univ. of Korea, Seoul, Korea
March 2009 – February 2013 Clinical Fellow,
Catholic blood and Marrow Transplantation Center,
The Catholic Univ. of Korea, Seoul, Korea
March 2013 – February 2016 Clinical assistant professor,
Department of Hematology, Seoul St. Mary's Hospital,
The Catholic University of Korea
March 2016 – March 2018 Assistant professor,
Department of Hematology, Seoul St. Mary's Hospital,
The Catholic University of Korea
March 2018 – November 2019 Postdoctoral Fellow,
MD Anderson cancer center
April 2018 – Associate professor,
Department of Hematology, Seoul St. Mary's Hospital,
The Catholic University of Korea

• **Professional Organizations**

1. Korean Society of Hematology
2. Korean Society of Hematopoietic Stem Cell Transplantation
3. Korean Society of Internal Medicine
4. Korean Medical Association

• **Main Scientific Publications:**

(Recent 5 years, Published in SCI/SCIE journals)

1. Lee SE, Min GJ, Park SS, et al. Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study. Biol Blood Marrow Transplant. 2020;26(10):1906-1914.
2. Lee S-E, Wang F, Trujillo-Ocampo A, et al. Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes. eJHaem 2020;1(2):552-557.
3. Lee SE, Hyun Kong J, Kim SH, et al. Change of right ventricular systolic pressure can indicate

- dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia. *Cancer Med.* 2021;10(5):1515-1524.
4. Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. *Expert Opin Drug Saf.* 2021;20(2):171-179.
 5. Lee SE, Lim JY, Ryu DB, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. *Biol Blood Marrow Transplant* 2019; 25(10):1933-1943
 6. Lee SE, Lim JY, Kim TW, et al. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. *J Immunother Cancer* 2019; 7(1):35-47.
 7. Lee SE, Park SS, Jeon YW, et al. Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose. *Am J Hematol* 2018; 93(11):1368-1375.
 8. Lee SE, Jeon YW, Yoon JH, et al. Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents. *Blood Res* 2018;53(2):123-129.
 9. Lee SE, Lim JY, Ryu DB, et al. Low frequency of CD3⁺CD4⁺CD161⁺ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment. *Ann Hematol* 2018; 97(11):2163-2171.
 10. Lee SE, Choi SY, Kim SH, et al. Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. *Leuk Res* 2018;[Epub ahead of print]
 11. Lee SE, Lee JY, Han AR, et al. Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia. *Transl Oncol* 2018; 11(3):567-574.
 12. Lee SE, Lim JY, Ryu DB, et al. Circulating CD3⁺CD4⁺CD161⁺ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma. *Biomed Res Int* 2018; [Epub ahead of print].
 13. Jung SH, Lee SE, Lee M, et al. Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. *Haematologica.* 2017;102(11):e456-e459. (Jung SH and Lee SE equally contributed in this study.)
 14. Lee SE, Lim JY, Kim TW, et al. Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2018;24(1):32-42. (Lee SE and Lim JY equally contributed in this study.)
 15. Batsukh K, Lee SE, Min GJ, et al. Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma. *Immune Netw.* 2017;17(4):250-260. (Corresponding author)
 16. Lee SE, Park SS, Jeon YW, et al. Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia. *Eur J Haematol.* 2017;99(4):336-343.
 17. Lee SE, Choi K, Han S, et al. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. *Anticancer Drugs.* 2017;28(6):660-668.
 18. Lee SE, Choi SY, Kim SH, et al. Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy. *Leuk Lymphoma.* 2018;59(1):105-113